IQVIA Holdings Inc. (NYSE:IQV) Short Interest Update

IQVIA Holdings Inc. (NYSE:IQV - Get Free Report) saw a large drop in short interest in the month of March. As of March 31st, there was short interest totalling 3,150,000 shares, a drop of 17.3% from the March 15th total of 3,810,000 shares. Approximately 1.8% of the shares of the stock are sold short. Based on an average trading volume of 1,660,000 shares, the short-interest ratio is currently 1.9 days.

IQVIA Stock Up 2.4 %

NYSE IQV traded up $3.42 during trading on Wednesday, reaching $147.03. The company's stock had a trading volume of 2,294,957 shares, compared to its average volume of 1,418,414. The business has a 50-day moving average price of $174.25 and a 200-day moving average price of $195.42. IQVIA has a 1-year low of $135.97 and a 1-year high of $252.88. The stock has a market capitalization of $25.92 billion, a PE ratio of 19.60, a PEG ratio of 1.99 and a beta of 1.46. The company has a current ratio of 0.84, a quick ratio of 0.84 and a debt-to-equity ratio of 2.12.

IQVIA (NYSE:IQV - Get Free Report) last announced its quarterly earnings results on Thursday, February 6th. The medical research company reported $2.90 earnings per share for the quarter, missing analysts' consensus estimates of $3.11 by ($0.21). IQVIA had a return on equity of 28.81% and a net margin of 8.91%. On average, research analysts forecast that IQVIA will post 10.84 earnings per share for the current fiscal year.

Hedge Funds Weigh In On IQVIA

Several institutional investors and hedge funds have recently added to or reduced their stakes in IQV. American National Bank & Trust acquired a new position in shares of IQVIA in the 1st quarter worth approximately $26,000. Synergy Asset Management LLC acquired a new position in shares of IQVIA in the 4th quarter worth approximately $33,000. Golden State Wealth Management LLC boosted its stake in IQVIA by 295.5% in the first quarter. Golden State Wealth Management LLC now owns 174 shares of the medical research company's stock worth $31,000 after purchasing an additional 130 shares in the last quarter. ST Germain D J Co. Inc. increased its position in IQVIA by 66.1% in the 1st quarter. ST Germain D J Co. Inc. now owns 191 shares of the medical research company's stock valued at $34,000 after acquiring an additional 76 shares in the last quarter. Finally, GKV Capital Management Co. Inc. bought a new stake in shares of IQVIA during the fourth quarter valued at approximately $39,000. 89.62% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several analysts have issued reports on IQV shares. Citigroup reduced their price target on shares of IQVIA from $225.00 to $210.00 and set a "neutral" rating on the stock in a report on Tuesday, March 4th. Mizuho reduced their target price on IQVIA from $242.00 to $210.00 and set an "outperform" rating on the stock in a research report on Wednesday, April 9th. Truist Financial reduced their target price on IQVIA from $263.00 to $216.00 and set a "buy" rating on the stock in a report on Thursday, April 10th. StockNews.com cut shares of IQVIA from a "buy" rating to a "hold" rating in a research report on Wednesday, March 12th. Finally, Royal Bank of Canada reiterated an "outperform" rating and set a $270.00 target price on shares of IQVIA in a report on Monday, February 10th. Six analysts have rated the stock with a hold rating, sixteen have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $241.50.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.